Show simple item record

dc.contributor.authorMunir, T
dc.contributor.authorRawstron, A
dc.contributor.authorBrock, K
dc.contributor.authorVicente, S
dc.contributor.authorYates, F
dc.contributor.authorBishop, R
dc.contributor.authorMacdonald, D
dc.contributor.authorFegan, C
dc.contributor.authorMcCaig, A
dc.contributor.authorSchuh, A
dc.contributor.authorPettitt, A
dc.contributor.authorGribben, J
dc.contributor.authorPatten, P
dc.contributor.authorDevereux, S
dc.contributor.authorBloor, Adrian
dc.contributor.authorFox, C
dc.contributor.authorForconi, F
dc.contributor.authorHillmen, P
dc.date.accessioned2019-06-04T09:44:29Z
dc.date.available2019-06-04T09:44:29Z
dc.date.issued2019en
dc.identifier.citationMunir T, Rawstron A, Brock K, Vicente S, Yates F, Bishop R, et al. Ibrutinib plus venetoclax in relapsed/refractory CLL: results of the Bloodwise TAP Clarity study. Br J Haemat. 2019; 185:25.en
dc.identifier.urihttp://hdl.handle.net/10541/621837
dc.language.isoenen
dc.titleIbrutinib plus venetoclax in relapsed/refractory CLL: results of the Bloodwise TAP Clarity studyen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentSt James’s Institute of Oncology, Leeds Teaching Hospitalen
dc.identifier.journalBritish Journal of Haematologyen


This item appears in the following Collection(s)

Show simple item record